Gastrointestinal Cancer
245
55
69
99
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
32 trials with published results (13%)
Research Maturity
99 completed trials (40% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.8%
19 terminated out of 245 trials
83.9%
-2.6% vs benchmark
4%
9 trials in Phase 3/4
32%
32 of 99 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 99 completed trials
Clinical Trials (245)
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
Harvesting Cells for Experimental Cancer Treatments
Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy
Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery
Effect of Silkworm Pupa Tablets in Gastrointestinal Malignancies at Nutritional Risk Following Radical Surgery
Frailty in Patients With Gastrointestinal Cancer Who Are Undergoing Major Surgery
ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial
BOLSTER: Learning New Skills to Thrive
The SOAR Study: a Study of Geriatric Assessment and Exercise for Older Adults and Their Support Person
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery